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Effect of Oral Ferric Maltol on Iron Parameters in Patients with Chronic Kidney Disease (CKD)  
and Varying Degrees of Inflammation; a Randomized, Controlled Trial
Nelson P. Kopyt – Lehigh Valley Hospital, Allentown, PA, USA 
On behalf of the AEGIS-CKD Study Group
Background
• Iron-deficiency anemia (IDA) is a leading cause of morbidity 
and mortality in patients with CKD1,2
 – Intravenous iron administration can be inconvenient and 
risks allergic reactions or iron overload3,4
 – Oral ferrous treatments are associated with 
gastroenterological adverse events that can significantly 
impair compliance and efficacy5
 – Some patients with CKD have chronic inflammation, which 
can reduce the absorption and utilization of iron6
• Patients with CKD and IDA would therefore benefit from an 
oral iron-replacement therapy that is tolerable and effective 
irrespective of the degree of underlying inflammation
• Ferric maltol is an oral iron-replacement therapy formulated to 
improve gastrointestinal (GI) absorption (Figure 1)
• AEGIS-CKD was a phase III multicenter, randomized controlled 
trial (NCT02968368) to evaluate the efficacy of oral ferric maltol 
versus placebo in the treatment of IDA in adults with CKD 
(Figure 2)
 – Primary results for AEGIS-CKD will be presented separately 
(abstract #FR-OR120); here we report changes in iron 
storage indices for subgroups based on the degree of 
chronic inflammation as assessed by high-sensitivity 
C-reactive protein (hsCRP) levels
 – CRP is notably higher in patients with CKD than in patients 
with less kidney impairment:7
Methods
• hsCRP was measured at baseline
• Changes in iron parameters (ferritin, transferrin saturation 
[TSAT], and serum iron) were assessed at weeks 4, 8, and 16
• hsCRP subgroups were based on the standard ranges for 
cardiovascular risk: low (<1 mg/L), moderate (≥1 to ≤3 mg/L), 
and high (>3 mg/L)
• Analyses of change from baseline to week 16 were carried out 
on the intent-to-treat (ITT) population (all randomized patients) 
 – The least-squares mean (LSM) change from baseline was 
determined by analysis of covariance with treatment as a 
factor and continuous covariates of baseline Hb and eGFR
 – Changes in iron parameters were based on observed data, 
with last observation carried forward (LOCF)
Conclusion
• Ferric maltol improved iron storage parameters – ferritin and 
TSAT – from baseline to week 16 vs placebo in patients with 
IDA and CKD irrespective of the degree of underlying chronic 
inflammation
Results
• 167 patients were randomized, 111 to ferric maltol and 56 
to placebo (Table 1); all patients were included in the hsCRP 
subgroup analysis
 – 129 (77%) patients completed 16 weeks of treatment (19 [81%] 
in the ferric maltol group and 39 [70%] in the placebo group)
• At week 16
 – All iron parameters were significantly improved with ferric 
maltol vs placebo (abstract #FR-OR120)
 – The mean change from baseline in ferritin was 25.49 µg/dL 
(SD 5.400) with ferric maltol and –8.25 µg/dL (SD 7.614) 
with placebo (p=0.0004)
° Consistent results were seen regardless of degree of 
underlying inflammation, as measured by baseline 
hsCRP level (Figure 3) 
 – The mean change from baseline in TSAT was 3.78%  
(SD 0.638) with ferric maltol and –0.69% (SD 0.900) with 
placebo (p<0.0001)
° As with ferritin, consistent results were seen regardless 
of degree of underlying inflammation (Figure 4)











Figure 2. Study design
BID, twice daily; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; R, randomization; TSAT, transferrin saturation.
Figure 3. Mean change in ferritin from baseline to week 16 by 
hsCRP level at baseline (ITT population, LOCF)
Figure 4. Mean change in TSAT from baseline to week 16 by 
hsCRP level at baseline (ITT population, LOCF)
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 ◦ Estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2 = mean hsCRP 4.10 mg/L (95% confidence 
interval [CI] 1.9–10.2) 
 ◦ eGFR >60 mL/min/1.73 m2 = mean hsCRP 1.75 mg/L 
(95% CI 0.95–3.33) (p<0.001)
Figure 1. Mechanism of action of oral ferric maltol
Ferric maltol is a complex of ferric iron (Fe3+) and three maltol ligands. Maltol 
is a sugar derivative found in many food products; it strongly chelates iron in the 
ferric form so that it is stable and available for absorption. 
Before absorption, the ferric iron and maltol complex remains intact in the 
intestinal lumen, minimizing the risk of GI toxicity associated with free radicals 
produced by free iron. On absorption, ferric iron is bound to the iron transport 
receptor, and the maltol complex dissociates to be rapidly absorbed by diffusion, 
metabolized by glucuronidation, and eliminated by the kidneys.
Iron uptake with ferric maltol is saturable, avoiding the potential for iron 











(up to week 52)
12 52
Stratification
by Hb and eGFR
2:1








eGFR ≥15 to <60 mL/min/1.73 m2
Hb ≥8.0 to <11.0 g/dL 
  and ferritin <250 µg/L  
  + TSAT <25%
  or ferritin <500 µg/L
  + TSAT <15%
Primary efficacy endpoint
Change in Hb concentration 
from baseline to week 16









Age, years Mean (SD) 68.5 (12.4) 65.2 (12.8) 67.4 (12.6)
Sex, n (%) Female 78 (70.3) 39 (69.6) 117 (70.1)
Male 33 (29.7) 17 (30.4) 50 (29.9)
Race, n (%) Asian 2 (1.8) 0 2 (1.2)
American Indian 1 (0.9) 0 1 (0.6)
African American 23 (20.7) 12 (21.4) 35 (21.0)
White 81 (73.0) 42 (75.0) 123 (73.7)
Other 4 (3.6) 2 (3.6) 6 (3.6)
Hb, g/dL Mean (SD) 10.06 (0.769) 10.03 (0.817) 10.05 (0.783)
<9.5, n (%) 21 (18.9) 11 (19.6) 32 (19.2)
≥9.5, n (%) 90 (81.1) 45 (80.4) 135 (80.8)
eGFR, mL/
min/1.73 m2
Mean (SD) 31.9 (11.53) 29.7 (10.56) 31.1 (11.23)
≤30, n (%) 59 (53.2) 30 (53.6) 89 (53.3)
>30, n (% 52 (46.8) 26 (46.4) 78 (46.7)
hsCRP range, 
n (%)
<1 mg/L 22 (19.8) 9 (16.1) 31
≥1 to ≤3 mg/L 26 (23.4) 17 (30.4) 43
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